CytoMed Therapeutics (NASDAQ:GDTC) Given a $4.16 Price Target by Fundamental Research Analysts

CytoMed Therapeutics (NASDAQ:GDTC) has been given a $4.16 price objective by analysts at Fundamental Research in a research note issued on Tuesday, BayStreet reports. The firm presently has a “buy” rating on the stock. Fundamental Research’s price target would suggest a potential upside of 418.06% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.16.

CytoMed Therapeutics Price Performance

Shares of NASDAQ GDTC traded down $0.05 during mid-day trading on Tuesday, reaching $0.80. The company had a trading volume of 12,529 shares, compared to its average volume of 238,989. The business’s 50-day simple moving average is $0.91 and its 200 day simple moving average is $1.00. CytoMed Therapeutics has a one year low of $0.68 and a one year high of $3.68. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.06.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.